RA Capital Management, L.P. is a Boston-based venture capital firm that specializes in early and multi-stage investments in the healthcare and life sciences sectors. Founded in 2001, the firm focuses on companies developing drugs, medical devices, diagnostics, and biotechnology. RA Capital invests in a range of funding stages, from seed funding to later rounds, and is known for its willingness to invest under $1 million in initial rounds or larger sums in established companies. The firm's investment strategy emphasizes companies with promising technologies and products, particularly in areas like prevention, cost-effective diagnostics, genetic testing, and personalized medicine. The team consists of professionals with backgrounds in biology, chemistry, and medicine, enabling them to provide valuable insights into data, regulatory processes, and market demands. Additionally, RA Capital often seeks to co-invest and take board positions in its portfolio companies, enhancing their strategic growth opportunities.

OrbiMed Advisors LLC is a healthcare-focused investment firm founded in 1989, headquartered in New York City, with additional offices in various global locations. The firm manages approximately $5 billion in assets and specializes in private equity and venture capital investments across the healthcare sector, including pharmaceuticals, biotechnology, medical devices, and healthcare services. OrbiMed invests in companies at various stages, from early startups to established multinationals, and typically seeks to take majority stakes in its private equity investments. The firm employs fundamental analysis to guide its investment decisions and offers a range of financial services, including debt financing and structured capital, to both public and private healthcare companies. OrbiMed's investment strategy encompasses a broad spectrum of healthcare-related opportunities, targeting investments globally, primarily in North America, Europe, and Asia.

Novo Holdings, established in 1999 and based in Copenhagen, is the asset manager for the Novo Nordisk Foundation, overseeing its wealth and investments. The company primarily focuses on the life sciences sector, investing across various stages of company development, from early-stage ventures to established firms. Novo Holdings also manages a diversified portfolio of financial investments, including equity and fixed income securities. It is recognized as a leading life science investor globally and aims to generate long-term value to support the Foundation's grant obligations for medical and scientific research. Additionally, it plays a pivotal role in the Novo Group, maintaining a significant influence over its associated companies, including Novo Nordisk and Novozymes, while ensuring compliance with the group’s shared values and management principles. Through initiatives like Novo Seeds, the firm supports early-stage applied research in Scandinavia, further solidifying its commitment to advancing health and welfare through strategic investments.

Perceptive Advisors LLC is an investment management firm founded in 1999 and headquartered in New York City, with an additional office in Boston. The firm specializes in the healthcare sector, focusing on biotechnology, pharmaceuticals, life sciences, diagnostics, digital health, medical devices, and healthcare services. It engages in venture capital and incubation, investing at various stages of a company's life cycle, including seed and Series A funding, as well as late-stage venture and public market investments. Perceptive Advisors employs a long/short equity strategy and utilizes hedging techniques, including equity options and index options, while conducting in-house research to inform investment decisions. The firm also manages separate client-focused equity portfolios and provides customized debt financing solutions through its Perceptive Credit Opportunities Fund. Its clientele includes institutional investors, financial institutions, investment funds, and high-net-worth individuals.

5Y Capital is a private equity and venture capital firm based in Shanghai, China, focused on seed, start-up, early venture, and growth capital investments. Founded in 2008 and previously known as Morningside Venture Capital, the firm manages approximately USD 5 billion in dual-currency funds, supported by global investors such as sovereign wealth funds, family offices, and endowments. 5Y Capital primarily invests in various sectors, including healthcare, technology, fintech, media, software, life sciences, and education, with a special emphasis on medical treatment, biotechnology, and digital health. The firm seeks opportunities in China and other emerging markets across Asia and the Pacific, aiming to support entrepreneurs in building innovative companies. 5Y Capital typically makes initial investments exceeding USD 500,000 per portfolio company and operates as a subsidiary of Morningside Group, which has been active in venture capital investments since 1992.

The Invus Group is a private equity firm based in New York, founded in 1985. It specializes in making direct and indirect investments in various stages of companies, focusing on special situations, venture capital, and growth equity. The firm manages an evergreen fund, which allows it significant flexibility in investment strategies and the types of companies it engages with, including those in consumer products, food, specialty retail, software, biotech, and medical devices. Invus emphasizes a tailored approach to each investment, recognizing the uniqueness of every business and the need for long-term commitment to foster transformation. The firm aligns its incentives with those of its partners and has a history of empowering owner-managers by reinvesting capital from a consistent group of European families. Invus operates from offices in New York, London, Paris, and Hong Kong and manages assets exceeding $4 billion.

Wellington Management Company LLP, founded in 1928 and headquartered in Boston, Massachusetts, is a prominent investment management firm providing comprehensive solutions to institutional clients worldwide. The firm specializes in a diverse range of investment strategies, including equity, fixed income, multi-asset, and alternative investments, tailored to meet the unique return and risk objectives of its clients. Wellington Management employs a collaborative approach, leveraging proprietary research and analytical tools to identify opportunities and manage risks across global capital markets. The firm caters to a wide array of clients, including sovereign institutions, endowments, foundations, wealth managers, and insurance companies, spanning more than 50 countries. With a focus on long-term investment principles, Wellington Management fosters independent thought and debate within its teams, ensuring that resources are effectively utilized to deliver consistent results. The firm also emphasizes environmental, social, and governance (ESG) considerations in its research and investment processes, engaging with companies on key ESG topics.

Versant Ventures is a prominent healthcare investment firm founded in 1999 and headquartered in San Francisco, California. The firm focuses on investing in various sectors within healthcare, including biotechnology, pharmaceuticals, medical devices, and life sciences, and operates at all stages of company development. With $2.3 billion in assets under management, Versant Ventures emphasizes the discovery and development of innovative therapeutics, leveraging a team with substantial investment, operational, and scientific expertise to take a hands-on approach in building companies. The firm has a strong track record, with over 65 of its portfolio companies achieving successful acquisitions or public offerings. Versant maintains offices in Canada, the U.S., and Europe, allowing for a global investment reach.

Vivo Capital, LLC is a private equity and venture capital firm founded in 1996 and headquartered in Palo Alto, California, with additional offices in Asia. The firm specializes in healthcare investments across various stages, including early stage, growth capital, and public equity. With approximately $5.8 billion in assets under management, Vivo has invested in over 290 public and private companies globally. Its focus lies primarily in biopharmaceuticals, specialty pharmaceuticals, medical devices, and healthcare services, targeting companies in the U.S. and East Asia, particularly China. Vivo aims to invest between $2 million and $40 million, typically favoring minority equity stakes. The firm's multi-disciplinary team includes professionals with backgrounds in medicine, science, and entrepreneurship, allowing it to effectively navigate the complexities of the healthcare sector.

Innovate UK is a non-departmental public body established in 2007 and based in Swindon, United Kingdom. Funded by a government grant, it supports innovation in science and technology by providing funding services to businesses across various sectors and regions. The organization aims to drive productivity and economic growth by facilitating advancements that contribute to the UK’s economic landscape. In addition to funding, Innovate UK offers a range of services and information related to business and economic development, thereby fostering a supportive environment for innovation.

SOSV is a global venture capital firm founded in 1995 and headquartered in Princeton, New Jersey. Specializing in seed-to-growth stage investments, SOSV operates multiple accelerator programs worldwide, including HAX for hardware, IndieBio and RebelBio for life sciences, Chinaccelerator and MOX for cross-border internet ventures, Food-X for innovative food solutions, and dlab for blockchain technology. The firm focuses on investments in revolutionary deep technologies aimed at improving human and planetary health, as well as cross-border markets, particularly in Asia. SOSV invests in approximately 150 startups annually, providing support through its resources to accelerate product development and scaling. Over its two-decade history, SOSV has established a strong reputation, consistently ranking among the top venture capital firms globally.

Samsara BioCapital LLC is a principal investment firm founded in 2016 and based in Palo Alto, California. The firm specializes in investing in biotechnology companies across the United States, with a focus on sectors such as pharmaceuticals, oncology, life sciences, and digital health. As a registered investment adviser, Samsara BioCapital aims to support innovative healthcare ventures through strategic investments.

The EIC pilot supports top-class innovators, entrepreneurs, small companies and scientists with bright ideas and the ambition to scale up internationally. It brings together the parts of Horizon 2020 that provide funding, advice and networking opportunities for those at cutting edge of innovation.

Pfizer Inc., founded in 1849 and based in the United States, is one of the world's largest pharmaceutical companies, specializing in the development and sale of prescription drugs and vaccines. With annual sales nearing $50 billion, the company focuses on improving health outcomes by providing safe, effective, and affordable medicines. Pfizer has a diverse portfolio that includes leading products such as the pneumococcal vaccine Prevnar 13, the cancer treatment Ibrance, and the cardiovascular medication Eliquis. The majority of its sales come from prescription drugs and vaccines, with nearly half of its revenue generated from international markets, particularly emerging economies. Pfizer is committed to addressing significant health care challenges through scientific innovation and aims to ensure access to essential health care services for people worldwide.

Alexandria Venture Investments, LLC is a venture capital firm established in 1996 and headquartered in Pasadena, California. As the strategic investment arm of Alexandria Real Estate Equities, it focuses on providing capital to seed, early-stage, and growth-stage companies within the healthcare sector. The firm emphasizes investments in biopharma, diagnostics, life sciences, research tools, agrifoodtech, and agtech. Alexandria Venture Investments aims to support innovative entities developing breakthrough technologies and therapies, leveraging its extensive industry knowledge and relationships with leading investors. Its approach is characterized by a commitment to fostering innovation and entrepreneurship in the life sciences and technology sectors.

New Enterprise Associates, Inc. is a global venture capital and private equity firm based in Menlo Park, California, founded in 1977. The firm specializes in investments across various stages of company development, from seed and startup to later-stage growth and public investments. With over $19 billion in cumulative committed capital, NEA focuses on technology and healthcare sectors, particularly in areas such as consumer internet, financial technology, software, healthcare services, life sciences, and energy technology. The firm also invests in semiconductor companies and alternative energy initiatives in India. NEA has a proven track record, with more than 210 portfolio company IPOs and over 360 acquisitions. The firm's investment strategy encompasses a global perspective, targeting opportunities in North America, Asia, and South America, and typically involves investments ranging from $0.05 million to $20 million.

ARCH Venture Partners is a private equity and venture capital firm founded in 1986 and based in Chicago, Illinois. It specializes in investing in early-stage and later-stage technology companies, primarily focusing on life sciences, biotechnology, advanced materials, and various tech sectors such as clean technology, software, and communications. The firm is recognized for its role in commercializing innovations developed at academic research institutions and national laboratories. ARCH typically begins with conservative seed investments to mitigate risk, later leading or co-leading funding rounds up to liquidity. With a national scope and a regional focus, it targets underserved geographic markets and seeks to invest in companies addressing neurodegenerative diseases and mental health issues. ARCH has raised over $3 billion through ten venture funds and has invested in more than 150 companies, with a preference for co-founding partnerships with leading scientists and entrepreneurs. Its investors include major corporations, pension funds, and private investors.

The National Science Foundation (NSF), established in 1950 and located in Alexandria, Virginia, is an independent federal agency dedicated to advancing fundamental research and education across all scientific and engineering disciplines. With an annual budget of approximately $7.8 billion, the NSF operates America's Seed Fund, which allocates nearly $200 million each year to support startups and small businesses through the Small Business Innovation Research (SBIR) program. This initiative provides non-dilutive funding of up to $1.5 million to assist in research and development efforts, thereby facilitating the transformation of scientific discoveries into commercially viable products and services. By helping to de-risk technology, the NSF plays a crucial role in fostering innovation and addressing societal challenges through scientific advancements.

Deerfield Management is a healthcare investment management firm founded in 1994 and based in New York. With over $8 billion in assets, Deerfield specializes in long-term structured investments across both public and private healthcare companies, including pharmaceuticals, biotechnology, life sciences, and healthcare technology. The firm typically holds equity or debt interests in more than 100 companies, ranging from early-stage drug research ventures to established healthcare service and medical device providers. Additionally, Deerfield is committed to philanthropy, donating a portion of its profits to the Deerfield Foundation. The Deerfield Institute employs various research methods to provide objective market intelligence, engaging with thousands of professionals annually to address complex healthcare issues.

GV Management Company, LLC, formerly known as Google Ventures, serves as the venture capital arm of Alphabet Inc., established in 2009 and headquartered in Mountain View, California, with additional offices in Boston, New York, Cambridge, and London. The firm specializes in growth capital investments across various stages, including seed, early, mid, and late stages, focusing on sectors such as life sciences, healthcare, artificial intelligence, robotics, cyber security, and agriculture. GV has invested in over 300 companies, seeking to support startups that aim to innovate and transform industries. The firm typically invests up to $50 million, with smaller amounts allocated to early-stage ventures. GV provides its portfolio companies with exceptional support by connecting them with Google's resources and talent, leveraging a team of experts in engineering, design, science, and marketing to enhance their growth potential.

Frazier Healthcare VI is a venture capital fund managed by Frazier Healthcare Partners, which was established in 1991 and is based in Seattle, Washington. The firm specializes in providing growth capital to companies within the healthcare sector, focusing on areas such as pharmaceuticals, biotechnology, medical devices, healthcare services, and life sciences. Frazier Healthcare VI invests across all stages of a company's development, from early-stage ventures to later-stage growth buyouts. The firm typically makes investments ranging from $3 million to $100 million, with a preference for companies that demonstrate profitability and have revenues between $50 million and $500 million. Frazier Healthcare Partners has a strong track record, having invested in over 170 healthcare companies and actively contributing to their growth through strategic guidance and leveraging extensive industry networks. The firm seeks opportunities primarily in the United States, Canada, and Europe, emphasizing its commitment to addressing unmet medical needs through innovation.

Logos Capital is an equity hedge fund manager based in San Francisco, California, founded in March 2019. The firm specializes in fundamental biotechnology investments, leveraging both in-house data analytics and scientific expertise to identify transformative therapies in healthcare. By combining medical, scientific, and statistical disciplines, Logos enhances its investment diligence to uncover compelling opportunities with uncorrelated market returns. The firm's approach integrates statistical modeling of clinical trials with rigorous scientific assessment, aiming to achieve high conviction in its investment positions. Logos Capital manages pooled investment vehicles and focuses on public equity markets, employing a blend of internal research and external insights to inform its investment strategies.

Boxer Capital LLC is a venture capital firm founded in 2005 and based in San Diego, California. As a subsidiary of Tavistock Life Sciences, it specializes in investing in both private and public companies within the biotechnology and life science sectors. Boxer Capital focuses on a wide range of companies involved in the drug development lifecycle, from early stage preclinical discovery assets to late stage clinical and commercial entities. The firm aims to support the growth and advancement of biotechnology innovations through its strategic investments.

The Redmile Group, established in 2007 and based in San Francisco with an additional office in New York, is a private equity firm that focuses on venture capital investments in the healthcare sector. The firm manages multiple funds, including Redmile Biopharma Investments II and III, which are dedicated to investing in the biopharma and broader healthcare industries. Through these investments, Redmile Group aims to support innovative companies that are advancing healthcare solutions.

Lilly Asia Ventures, founded in 2008, serves as the corporate venture capital arm of Eli Lilly and Company, focusing on investments in the life sciences and healthcare sectors, with a particular emphasis on opportunities in China. The firm targets promising companies at various stages of development, from seed to commercialization, and seeks to invest between $5 million and $15 million per round. Lilly Asia Ventures specializes in human therapeutics, medical technology, healthcare services, and broader life sciences, including industrial and agricultural biotechnology. With a preference for taking minority stakes, typically less than 20 percent, the firm aims to partner with companies that exhibit strong management teams and innovative business models. Headquartered in Shanghai, with additional offices in Hong Kong and California, Lilly Asia Ventures is committed to driving innovation in the healthcare landscape across East and South Asia.

Rock Springs Capital is a Baltimore, Maryland-based investment firm established in 2013 that focuses primarily on the healthcare and biotechnology sectors. The firm engages in early-stage investments while offering management services for security portfolios and portfolio management tailored for businesses and institutional clients. With a strategy that includes long/short equity, Rock Springs Capital aims to leverage opportunities within the healthcare industry to drive growth and deliver value to its investors.

Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, with additional offices in Beijing, Suzhou, and Hong Kong. Founded in 2006, the firm specializes in investing in early to growth-stage companies across various sectors, including healthcare, information technology, consumer products, media, and clean technology. Qiming has established itself as a leading investment firm in China, managing multiple funds with over $1 billion in assets. The firm focuses on supporting innovative entrepreneurs and companies that demonstrate high growth potential, particularly in the technology and healthcare landscapes. Through its strategic investments, Qiming aims to foster the development of new business models and technologies, contributing to the dynamic entrepreneurial ecosystem in China.

Bpifrance Financement S.A. is a French financial institution that provides a wide range of financing solutions and support services for businesses at various stages of their development. Established in 1980 and based in Maisons-Alfort, France, the company offers medium to long-term loans, export insurance, real estate and equipment leasing, and working capital loans. Bpifrance also invests in startups, small and medium-sized enterprises (SMEs), and mid-cap companies through direct investments and fund management activities. Additionally, it provides consulting services for executives and training for CEOs, aiming to facilitate innovation and growth. Bpifrance was formed from the merger of several entities in July 2013, including OSEO, CDC Entreprises, and FSI, to enhance its role in supporting the financing of the French economy.

Polaris Partners is a venture capital firm founded in 1996 and headquartered in Boston, Massachusetts. With additional offices in San Francisco and New York, the firm specializes in investing across all stages of technology and healthcare companies, including life sciences and biotechnology. Polaris has established a strong track record over its more than 20 years in the industry, focusing on partnering with repeat entrepreneurs and innovators who are enhancing quality of life and work. The firm's investments are directed primarily within the United States and Europe, supporting companies from their founding stages to profitable growth.

Sofinnova Partners is an independent venture capital firm headquartered in Paris, France, with a focus on the life sciences sector. Established in 1972, the firm has financed nearly 500 companies over its 45-year history, primarily investing in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations. Sofinnova Partners actively sources investment opportunities, often taking the lead as the first institutional investor in Series A financings. The firm plays a significant role in guiding its portfolio companies, participating on their boards, and supporting them from the formation phase through to exit. While its primary investment focus is in Europe, the firm also makes select investments globally, concentrating on healthcare and sustainability sectors within life sciences, including biopharmaceuticals, biotech, medical devices, and industrial biotechnology.

Eli Lilly & Company, founded in 1876 and headquartered in Indianapolis, Indiana, is a prominent American pharmaceutical firm engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical products. The company operates in various therapeutic areas, including neuroscience, cardiometabolic, cancer, and immunology, with key products such as Zyprexa, Cymbalta, Humalog, and Verzenio. Eli Lilly's products are distributed in approximately 135 countries, with manufacturing facilities in the United States, Puerto Rico, and 25 other nations. In addition to its commercial endeavors, the Eli Lilly & Company Foundation supports initiatives aimed at improving patient outcomes and educational opportunities for underserved communities, particularly in early childhood education and STEM fields.

Atlas Venture is a private equity and venture capital firm based in Cambridge, Massachusetts, founded in 1980. The firm specializes in early-stage investments, particularly in the life sciences and technology sectors, with a strong emphasis on biotechnology and personalized medicine. Atlas Venture adopts a seed-led venture creation strategy, rigorously selecting opportunities to build scalable businesses. It typically invests between $0.25 million and $15 million per transaction, preferring to be a lead investor and to obtain board representation in its portfolio companies. The firm primarily focuses on startups in the United States and Europe, particularly in New England and the San Francisco Bay Area. Since its inception, Atlas Venture has managed over $2 billion in committed capital and has been involved in the creation and growth of numerous companies, with many achieving significant exits through acquisitions or public offerings. The firm has distinct teams dedicated to life sciences and technology investments, allowing for specialized attention in these dynamic fields.

Novartis Venture Fund, established in 1996 and based in Basel, Switzerland, focuses on investing in the life sciences, biotechnology, oncology, and digital health sectors. The fund aims to develop innovative therapeutics, medical devices, diagnostics, and drug delivery systems, emphasizing unmet medical needs and clinical impact. Initial investments typically begin at a minimum of 100,000 USD, with the potential for total funding reaching 30 to 50 million USD per company throughout its lifecycle. The fund prefers to engage at early stages to help build companies, providing additional funding as they progress. Novartis Venture Fund is open to leading or co-leading investment deals and participating in larger syndicates across regions including the USA, Canada, Europe, and Asia-Pacific.

RTW Investments, LP is an employee-owned hedge fund manager based in New York, established in 2009. The firm specializes in a sector-oriented investment strategy, focusing primarily on the life sciences, big data, and digital health sectors in the United States and Europe. RTW Investments manages pooled investment vehicles and also offers separate client-focused equity and fixed income portfolios, including equity mutual funds. The firm emphasizes fundamental research and conducts in-house analyses to inform its investment decisions, aiming to capitalize on opportunities in both public equity and fixed income markets globally.

Forbion is a venture capital firm based in Naarden, Netherlands, established in 2006. It specializes in early-stage investments within the life sciences and MedTech sectors, focusing on companies involved in drug development and addressing critical medical needs. The firm has a team of nine investment professionals and has built a strong track record since the late 1990s, with successful investments in various notable companies. Forbion manages assets exceeding €400 million across three active funds and co-manages BioGeneration Ventures, which targets academic spin-outs and seed investments in the Netherlands. The firm continues to play a significant role in advancing innovative healthcare solutions through its strategic investments.

F Prime, Inc. is a venture capital firm based in Cambridge, Massachusetts, with additional offices in San Francisco and London. Founded in 1969, it has a strong legacy rooted in Fidelity Investments, which has been a significant player in asset management since 1946. F Prime focuses on early-stage investments in North America and Europe, primarily in the healthcare, life sciences, technology, therapeutics, fashion, medtech, and health information technology sectors. The firm operates several funds, including those dedicated to healthcare, oncology, life sciences, and health technology services. F Prime Capital Partners emphasizes supporting entrepreneurs without the pressure of external fundraising, allowing them to concentrate on identifying and nurturing promising companies.

Casdin Capital, LLC is a New York-based investment firm established in 2012, specializing in the life sciences and healthcare sectors. The firm focuses on venture capital investments across various areas, including oncology, digital health, agtech, and broader healthcare. It operates as a Registered Investment Adviser and manages a long-short equity fund. Casdin Capital engages in both early-stage and late-stage private investments, utilizing a fundamental research approach to identify promising opportunities in its target industries. As of October 2020, the firm manages approximately $2.2 billion in assets. The founder and Chief Investment Officer, Eli Casdin, has been instrumental in shaping the firm’s investment strategy and direction.

IP Group, founded in 2001 and based in London, is a venture capital investment firm focused on the commercialization of intellectual property from research-intensive institutions. The firm specializes in providing financial, strategic, and commercial expertise to facilitate the development of businesses in sectors such as clean technology, life sciences, and deep technology. By leveraging its extensive industry knowledge and financial acumen, IP Group effectively identifies and manages suitable intellectual property for commercialization, helping to create value for shareholders and partners. The firm has established a strong track record of delivering positive results through its strategic investments and partnerships, thereby enhancing the potential of innovative companies in its portfolio.

EcoR1 Capital, LLC is an employee-owned investment firm based in San Francisco, California, established in 2012. The firm specializes in managing pooled investment vehicles and separate client-focused equity and fixed income portfolios. EcoR1 Capital primarily invests in the public equity markets of the United States, employing a long/short strategy. The firm focuses on the biotechnology sector, as well as the broader healthcare, life sciences, and oncology sectors. As a Registered Investment Adviser (RIA), EcoR1 Capital aims to generate returns for its clients through strategic investments in these fields.

Nextech Invest is a Zurich-based venture capital and private equity firm established in 1998, specializing in early, mid-stage, and late-stage investments within the healthcare and life sciences sectors. The firm focuses on companies developing innovative therapies, diagnostics, medical technologies, and services, with a particular emphasis on oncology. Nextech Invest seeks evidence of efficacy in preclinical animal models or device prototypes that meet specific requirements before considering investments. It primarily targets investments ranging from CHF 1 million to CHF 5 million per financing round and aims to secure a Board position in its portfolio companies. The firm is interested in global opportunities, particularly in Africa, the Middle East, Asia, North America, and Europe, including Germany and Switzerland, and it is open to co-investments across the rest of Europe. Nextech Invest typically aims for exit strategies within three years through trade sales.

HBM Healthcare Investments is a principal investment firm established in 2001 and based in Zug, Switzerland, with a focus on the biotechnology, human medicine, diagnostics, and medical technology sectors. The firm invests globally in approximately 40 mature emerging companies, primarily targeting private firms that demonstrate significant value creation potential. Approximately two-thirds of its portfolio consists of investments in unquoted companies, while the remainder includes public companies and funds. HBM Healthcare Investments has developed a distinctive market position through its strategic investments in firms whose products are either at advanced stages of development or already available in the market. This diversified approach allows the firm to leverage opportunities across Europe, Asia, and North America, contributing to its broad shareholder base and enhancing its investment capabilities.

The Column Group is a venture capital firm based in San Francisco, California, specializing in investments in early-stage biotechnology companies, particularly in the drug discovery and development sector. Founded in 2005, the firm targets investments in areas such as cancer, inflammation, infectious diseases, metabolic disorders, cardiovascular diseases, and nervous system disorders. The Column Group typically invests between $15 million and $30 million per deal, providing support across all stages of development, from initial seed financing to later-stage commercialization. With a focus on fostering innovation in the healthcare and life sciences sectors, the firm aims to create the next generation of biotechnology companies in the United States.

MPM Capital is a healthcare investment firm based in Cambridge, Massachusetts, with an additional office in Brisbane, California. Founded in 1996, the firm specializes in early-stage investments within the biotechnology, healthcare, and life sciences sectors, focusing on companies that develop innovative therapeutic technologies, particularly in oncology, immunology, and neuroscience. MPM Capital actively invests in both public and private entities, seeking to translate scientific advancements into effective clinical outcomes. The firm targets investments ranging from $5 million to $50 million, emphasizing the importance of being a lead investor and often taking interim operating roles in its portfolio companies. With a dedicated team of investment professionals, MPM Capital aims to drive transformative medical breakthroughs that have the potential to significantly improve patients' lives.

SR One is the corporate venture capital arm of GlaxoSmithKline, established in 1985 and based in Redwood City, California. It focuses on investing globally in emerging life science companies that are developing innovative solutions aimed at significantly improving medical care. With a portfolio that encompasses biotechnology, healthcare, medical devices, and information technology sectors, SR One has invested approximately 800 million in over 180 companies since its inception. The firm is also recognized as a Registered Investment Adviser, further underscoring its commitment to fostering advancements in the life sciences through strategic investments.

Canaan VII is an early-stage venture capital fund managed by Canaan Partners, a firm founded in 1987 and based in San Francisco, California. Canaan Partners specializes in investing in innovative entrepreneurs, focusing primarily on the technology and healthcare sectors. The fund emphasizes investments in software and technology, media, and telecommunications. Over its 30 years of operation, Canaan has successfully managed over $5 billion in assets and completed more than 190 exits, demonstrating a strong track record in nurturing and scaling companies. With a team experienced in technology, infrastructure, communications, and life sciences, Canaan is committed to supporting promising ventures across a range of industries, ensuring it targets high-potential opportunities in the United States.

Fidelity Investments, founded in 1946 and headquartered in Boston, Massachusetts, is a privately owned investment management firm that offers a wide range of financial services. These services include individual retirement accounts (IRAs), 401(k) rollovers, annuities, discount brokerage, retirement planning, estate planning, wealth management, and life insurance. The firm caters to individual investors, businesses, financial advisors, and institutions, managing equity, fixed income, and balanced mutual funds. Fidelity invests in global public equity and fixed income markets, employing in-house research to inform its investment decisions. The firm serves over 32 million individuals, assists more than 22,000 businesses in managing employee benefits, and provides support to over 13,000 financial institutions with innovative solutions. Fidelity operates through numerous regional offices and Investor Centers across the United States.

Omega Funds is a Boston-based private equity and venture capital firm founded in 2004, specializing in early-stage investments within the healthcare and biotechnology sectors across North America and Western Europe. The firm focuses on various areas, including life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software as a service. By leveraging the expertise of institutional portfolio managers, Omega Funds provides investors with opportunities to diversify their investment portfolios with a minimum commitment. The firm is also a Registered Investment Adviser, ensuring compliance with regulatory standards in managing investments.

The Michael J. Fox Foundation for Parkinson's Research is a nonprofit organization based in New York, established in 2000 by Deborah Brooks. The foundation is dedicated to finding a cure for Parkinson's disease and developing improved therapies for individuals currently living with the condition. It achieves its mission through a well-funded and targeted research program, actively engaging a diverse community that includes scientists, Parkinson's patients, business leaders, clinical trial participants, donors, and volunteers. By fostering collaboration and innovation in the field of Parkinson's research, the foundation aims to accelerate progress and enhance the quality of life for those affected by the disease.

Sofinnova Ventures V is a venture capital fund based in Menlo Park, California, focusing on early-stage investments in life sciences and information technology. Established in 1974, the firm specializes in seed, startup, and mid-stage funding, primarily targeting clinical-stage biopharmaceutical companies, biotechnology innovations, and therapeutic drug development within life sciences. Key therapeutic areas include oncology, respiratory, dermatology, and neurology. In the information technology sector, Sofinnova Ventures V seeks to invest in product-oriented companies developing new systems, enterprise software, and telecommunications infrastructure. The firm typically makes initial investments ranging from $3 million to $15 million, with total investments reaching up to $30 million for life science ventures. It emphasizes active involvement in portfolio companies by requiring a board seat for early-stage investments. Sofinnova Ventures V operates in both the United States and Europe, primarily focusing on the West Coast while also considering opportunities on the East Coast and in developed European markets.

Foresite Capital is a multi-stage investment firm specializing in healthcare and life sciences, managing $2 billion in assets. Established in 2011, the firm focuses on growth equity investments across various sectors, including pharmaceuticals, biotechnology, and healthcare technology. Foresite Capital employs a data-driven and scientific approach to its investment analysis, collaborating closely with portfolio companies through a multidisciplinary team of professionals, including scientists, engineers, analysts, and clinicians. This collaborative strategy aims to address significant unmet clinical needs by supporting promising businesses at different stages of their development. The firm places particular emphasis on companies that leverage data science and machine intelligence within the healthcare sector. Foresite Capital is headquartered in San Francisco, with an additional office in New York.